Genome-Wide and Locus Specific Alterations in CDC73/HRPT2-Mutated Parathyroid Tumors

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Sulaiman, Luqman ^a   Haglund, Felix ^a   Hashemi, Jamileh ^a   Obara, Takao ^b   Nordenström, Jörgen ^a   Larsson, Catharina ^a   Juhlin, C Christofer ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b TOKYO WOMEN S MEDICAL UNIVERSITY MEDICAL CENTER EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CDC73 GENE; CHROMOSOME 13; CHROMOSOME 1P; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA METHYLATION; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DOSAGE; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HRPT2 GENE; HUMAN; HUMAN TISSUE; MALE; MICROARRAY ANALYSIS; PARATHYROID ADENOMA; PARATHYROID CARCINOMA; PARATHYROID TUMOR; POLYMERASE CHAIN REACTION; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE;

ADENOMA; BASE SEQUENCE; CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETIC ANALYSIS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MOLECULAR SEQUENCE DATA; MUTATION RATE; ORGAN SPECIFICITY; PARATHYROID NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 84867026801     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046325     Document Type: Article

References (37)

1. Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, et al. (2002) HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet 32: 676-680.
2. Cavaco BM, Guerra L, Bradley KJ, Carvalho D, Harding B, et al. (2004) Hyperparathyroidism-jaw tumor syndrome in Roma families from Portugal is due to a founder mutation of the HRPT2 gene. The Journal of clinical endocrinology and metabolism 89: 1747-1752.
3. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, et al. (2004) Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. The Journal of clinical endocrinology and metabolism 89: 96-102.
4. Villablanca A, Calender A, Forsberg L, Hoog A, Cheng JD, et al. (2004) Germline and de novo mutations in the HRPT2 tumour suppressor gene in familial isolated hyperparathyroidism (FIHP). J Med Genet 41: e32.
5. Shattuck TM, Välimäki S, Obara T, Gaz RD, Clark OH, et al. (2003) Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med 349: 1722-1729.
6. Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, et al. (2003) HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet 40: 657-663.
7. Cetani F, Pardi E, Borsari S, Viacava P, Dipollina G, et al. (2004) Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. The Journal of clinical endocrinology and metabolism 89: 5583-5591.
8. Bradley KJ, Cavaco BM, Bowl MR, Harding B, Cranston T, et al. (2006) Parafibromin mutations in hereditary hyperparathyroidism syndromes and parathyroid tumours. Clin Endocrinol (Oxf) 64: 299-306.
9. Sulaiman L, Nilsson IL, Juhlin CC, Haglund F, Hoog A, et al. (2012) Genetic characterization of large parathyroid adenomas. Endocrine-related cancer.
10. Juhlin CC, Nilsson IL, Johansson K, Haglund F, Villablanca A, et al. (2010) Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr Pathol 21: 166-177.
11. Krebs LJ, Shattuck TM, Arnold A, (2005) HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab 90: 5015-5017.
12. Bradley KJ, Bowl MR, Williams SE, Ahmad BN, Partridge CJ, et al. (2007) Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal. Oncogene 26: 1213-1221.
13. Lin L, Czapiga M, Nini L, Zhang JH, Simonds WF, (2007) Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism-jaw tumor syndrome enhances its proapoptotic function. Molecular cancer research: MCR 5: 183-193.
14. Yang YJ, Han JW, Youn HD, Cho EJ, (2010) The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Research 38: 382-390.
15. Woodard GE, Lin L, Zhang JH, Agarwal SK, Marx SJ, et al. (2005) Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression. Oncogene 24: 1272-1276.
16. Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, et al. (2005) The parafibromin tumor suppressor protein is part of a human Paf1 complex. Molecular and cellular biology 25: 612-620.
17. Chaudhary K, Deb S, Moniaux N, Ponnusamy MP, Batra SK, (2007) Human RNA polymerase II-associated factor complex: dysregulation in cancer. Oncogene 26: 7499-7507.
18. Farber LJ, Kort EJ, Wang P, Chen J, Teh BT, (2010) The tumor suppressor parafibromin is required for posttranscriptional processing of histone mRNA. Mol Carcinog 49: 215-223.
19. Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, et al. (2005) The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Mol Cell Biol 25: 5052-5060.
20. Mosimann C, Hausmann G, Basler K, (2006) Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 125: 327-341.
21. Gill AJ, Clarkson A, Gimm O, Keil J, Dralle H, et al. (2006) Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol 30: 1140-1149.
22. Juhlin C, Larsson C, Yakoleva T, Leibiger I, Leibiger B, et al. (2006) Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer 13: 509-523.
23. Juhlin CC, Haglund F, Obara T, Arnold A, Larsson C, et al. (2011) Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. Virchows Arch 459: 47-53.
24. Cetani F, Ambrogini E, Viacava P, Pardi E, Fanelli G, et al. (2007) Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol 156: 547-554.
25. Agarwal SK, Schrock E, Kester MB, Burns AL, Heffess CS, et al. (1998) Comparative genomic hybridization analysis of human parathyroid tumors. Cancer Genet Cytogenet 106: 30-36.
26. Farnebo F, Kytölä S, Teh BT, Dwight T, Wong FK, et al. (1999) Alternative genetic pathways in parathyroid tumorigenesis. J Clin Endocrinol Metab 84: 3775-3780.
27. Kytölä S, Farnebo F, Obara T, Isola J, Grimelius L, et al. (2000) Patterns of chromosomal imbalances in parathyroid carcinomas. Am J Pathol 157: 579-586.
28. Y Yi, Nowak NJ, Pacchia AL, Morrison C, (2008) Chromosome 11 genomic changes in parathyroid adenoma and hyperplasia: Array CGH, FISH, and tissue microarrays. Genes, Chromosomes and Cancer 47: 639-648.
29. Haven CJ, Howell VM, Eilers PH, Dunne R, Takahashi M, et al. (2004) Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res 64: 7405-7411.
30. Juhlin CC, Villablanca A, Sandelin K, Haglund F, Nordenstrom J, et al. (2007) Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer 14: 501-512.
31. Juhlin CC, Kiss NB, Villablanca A, Haglund F, Nordenstrom J, et al. (2010) Frequent Promoter Hypermethylation of the APC and RASSF1A Tumour Suppressors in Parathyroid Tumours. Plos One 5: 10.
32. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, et al. (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30: e15.
33. Hahn MA, Howell VM, Gill AJ, Clarkson A, Weaire-Buchanan G, et al. (2010) CDC73/HRPT2 CpG island hypermethylation and mutation of 5 ′-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors. Endocrine-Related Cancer 17: 273-282.
34. Shane E, (2001) Clinical review 122: Parathyroid carcinoma. J Clin Endocrinol Metab 86: 485-493.
35. Palanisamy N, Imanishi Y, Rao PH, Tahara H, Chaganti RS, et al. (1998) Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas. J Clin Endocrinol Metab 83: 1766-1770.
36. Välimäki S, Forsberg L, Farnebo LO, Larsson C, (2002) Distinct target regions for chromosome 1p deletions in parathyroid adenomas and carcinomas. Int J Oncol 21: 727-735.
37. Cryns VL, Yi SM, Tahara H, Gaz RD, Arnold A, (1995) Frequent loss of chromosome arm 1p DNA in parathyroid adenomas. Genes Chromosomes Cancer 13: 9-17.